Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Vaccinex Inc (NQ: VCNX ) 8.060 -0.500 (-5.84%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Vaccinex Inc < Previous 1 2 Next > Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease at the Alzheimer’s Association International Conference, Philadelphia, July 31, 2024 July 17, 2024 Pepinemab is believed to block astrocyte reactivity, a key pathology driving Alzheimer’s progression From Vaccinex, Inc. Via GlobeNewswire Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease June 06, 2024 From Vaccinex, Inc. Via GlobeNewswire Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update May 15, 2024 From Vaccinex, Inc. Via GlobeNewswire Vaccinex Reports 2023 Financial Results and Provides Corporate Update April 02, 2024 From Vaccinex, Inc. Via GlobeNewswire Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules March 27, 2024 From Vaccinex, Inc. Via GlobeNewswire Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology February 21, 2024 From Vaccinex, Inc. Via GlobeNewswire Vaccinex, Inc. Announces Reverse Stock Split February 15, 2024 From Vaccinex, Inc. Via GlobeNewswire Vaccinex Announces Pricing of $3.7 Million PIPE Financing February 07, 2024 From Vaccinex, Inc. Via GlobeNewswire Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule December 04, 2023 From Vaccinex, Inc. Via GlobeNewswire Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update November 13, 2023 From Vaccinex, Inc. Via GlobeNewswire Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting October 31, 2023 Pepinemab, anti-SEMA4D blocking antibody, appears to enhance clinical activity of immune checkpoint inhibitors via induction of highly organized tertiary immune structures in tumors of patients with... From Vaccinex, Inc. Via GlobeNewswire Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases October 26, 2023 Pepinemab, anti-SEMA4D blocking antibody, appears to inhibit astrocyte activation and brain inflammation as evidenced by significantly reduced levels of GFAP in patient blood From Vaccinex, Inc. Via GlobeNewswire Vaccinex Announces Pricing of $9.6 Million Public Offering September 28, 2023 From Vaccinex, Inc. Via GlobeNewswire Vaccinex’s Next Generation ActivMAb® Technology Published in mAbs, a Leading Biotech Journal, and Validated in OmniAb Proof-of-Concept Collaboration September 28, 2023 From Vaccinex, Inc. Via GlobeNewswire Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® Application September 27, 2023 From Vaccinex, Inc. Via GlobeNewswire Vaccinex Reports Groundbreaking Findings at Medical Conferences Supporting Development of Pepinemab for the Treatment of Neurodegenerative Diseases and Cancer September 26, 2023 From Vaccinex, Inc. Via GlobeNewswire Vaccinex, Inc. Announces Reverse Stock Split September 22, 2023 From Vaccinex, Inc. Via GlobeNewswire Vaccinex Reports Second Quarter 2023 Financial Results and Provides Corporate Update August 14, 2023 From Vaccinex, Inc. Via GlobeNewswire Vaccinex, Inc. to Participate in the Jefferies Healthcare Conference Track 6, on Friday, June 9, 2023 at 10:00 to 10:25 a.m. ET June 01, 2023 From Vaccinex, Inc. Via GlobeNewswire Vaccinex Reports First Quarter 2023 Financial Results and Provides Corporate Update May 15, 2023 From Vaccinex, Inc. Via GlobeNewswire Vaccinex Completes Enrollment in Phase 1b/2 SIGNAL-AD (Alzheimer’s Disease) Study of Pepinemab April 25, 2023 From Vaccinex, Inc. Via GlobeNewswire Vaccinex New ActivMAb® application published in Nature Communications for Directed Evolution of GPCRs in Mammalian Cells April 12, 2023 From Vaccinex, Inc. Via GlobeNewswire Vaccinex Announces Private Placement with Commitments of $5.0 Million April 03, 2023 From Vaccinex, Inc. Via GlobeNewswire Vaccinex Reports 2022 Financial Results and Provides Corporate Update of Continued Progress in Neurology and Oncology Clinical Programs April 03, 2023 From Vaccinex, Inc. Via GlobeNewswire Vaccinex, Inc. to Present at the 2023 AAIC Advancements: Immunity Conference March 23, 2023 March 24th presentation to highlight learnings related to pepinemab’s mechanism of action in both Huntington’s Disease and Alzheimer’s Disease From Vaccinex, Inc. Via GlobeNewswire Vaccinex Announces Initiation of Single-Arm Open Label, Phase Ib/2 Study to Evaluate Pepinemab in Combination with Avelumab as Second Line Combination Immunotherapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) March 21, 2023 From Vaccinex, Inc. Via GlobeNewswire Vaccinex Reports that KEYNOTE B-84 has Reached Targeted Enrollment for Pre-planned Interim Analysis March 09, 2023 From Vaccinex, Inc. Via GlobeNewswire MarketBeat Week in Review – 2/6 - 2/10 February 11, 2023 Markets are closed the week looking for direction as investors believe a soft landing is not possible and higher interest rates are likely Via MarketBeat Topics Artificial Intelligence Economy Exposures Artificial Intelligence Economy Interest Rates Should Investors Buy or Sell the Vaccinex Patent News? February 07, 2023 Shares of Vaccinex, Inc. are higher on February 7 on news that the clinical-stage biotechnology company secured a patent. Is it time to buy or sell the news? Via MarketBeat Topics Intellectual Property Exposures Intellectual Property Vaccinex Announces First Patient Dosed with Anti-CCR8 Antibody Licensed to Surface Oncology January 09, 2023 Surface Oncology initiates clinical trial with antibody discovered using Vaccinex’s ActivMAb® Antibody Discovery Platform From Vaccinex, Inc. Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.